Montelukast vs Nivolumab

## Montelukast vs Nivolumab: Overview

This comparison examines the pharmacological differences between **Montelukast** and **Nivolumab**.

## Mechanism of Action

**Montelukast**: Selective leukotriene D4 receptor antagonist.

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

## Pharmacokinetics

**Half-life**: Montelukast — 2.7-5.5 hours; Nivolumab — 27 days.

## Chemical Properties

**Molecular Formula**: Montelukast — C35H36ClNO3S; Nivolumab — N/A.

**Molecular Weight**: Montelukast — 586.1800 g/mol; Nivolumab — N/A.

**Type**: Montelukast — Small molecule; Nivolumab — Antibody.